Amgen Inc.’s migraine attack suppressant, Aimovig, has been granted marketing approval by the Japanese Ministry of Health, Labour and Welfare, the Thousand Oaks company announced Wednesday. ...

Subscribe to get the full story.


Are you a subscriber? Sign In